Pathologie (Heidelberg, Germany)最新文献_第6页

[Next generation tissue biobanking: quality assured, financed, and integrated?] [下一代组织生物库：质量保证、融资和整合？］

Pathologie (Heidelberg, Germany) Pub Date : 2024-11-01 Epub Date: 2024-11-13 DOI: 10.1007/s00292-024-01394-7

Katja Steiger, Angela Langer, Alexander Brobeil

{"title":"[Next generation tissue biobanking: quality assured, financed, and integrated?]","authors":"Katja Steiger, Angela Langer, Alexander Brobeil","doi":"10.1007/s00292-024-01394-7","DOIUrl":"10.1007/s00292-024-01394-7","url":null,"abstract":"Biobanks are essential for biomedical research, particularly in the era of personalized medicine. In Germany, 36 biobanks have been established over the past decade that are connected under the German Biobank Alliance (GBA). These biobanks store high-quality biological samples along with clinical data to support research projects. Biobanks can be integrated, handling both tissue and liquid samples, or set up as separate entities depending on specific requirements.Tissue biobanking is especially complex due to the invasive nature of tissue collection and the non-replicability of the samples. Close collaboration between clinics, pathologists, IT specialists, and biobank managers is crucial to ensure the quality of samples and promote interdisciplinary research.The integration of pathology and biobanking is key, both organizationally and technically. Shared IT systems, standardized protocols, and collaborative governance structures are vital for efficient data management. Quality assurance, ethical guidelines, and data protection are critical to maintaining public trust and legal compliance.Long-term financial models are needed to ensure the sustainability of biobanks. The GBA supports emerging biobanks through its \"Starterkit\" initiative, offering guidance and best practices to help new biobanks develop.Tissue biobanks are indispensable for advancing the understanding of diseases and developing new therapies. However, they must adhere to strict ethical and legal standards to maximize their scientific and societal value.","PeriodicalId":74402,"journal":{"name":"Pathologie (Heidelberg, Germany)","volume":" ","pages":"47-50"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142634246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Science and team spirit elate participants at the 107th Annual Meeting of the German Society for Patholgy in Munich]. [在慕尼黑举行的第107届德国病理学会年会上，科学和团队精神使与会者欢欣鼓舞]。

Pathologie (Heidelberg, Germany) Pub Date : 2024-11-01 Epub Date: 2025-01-02 DOI: 10.1007/s00292-024-01391-w

Beatrix Zeller, Carolin Mogler

引用次数: 0

[Cyst of Hattori-a rare lesion in the posterior mediastinum]. [服部囊肿--后纵隔的罕见病变]。

Pathologie (Heidelberg, Germany) Pub Date : 2024-11-01 Epub Date: 2024-05-10 DOI: 10.1007/s00292-024-01334-5

Felix Elsner, Koblandy Khamitov, Maximilian Hinsen, Horia Sirbu, Arndt Hartmann

引用次数: 0

Diagnostic and prognostic biomarkers for pancreatic neuroendocrine neoplasms. 胰腺神经内分泌肿瘤的诊断和预后生物标志物。

Pathologie (Heidelberg, Germany) Pub Date : 2024-11-01 Epub Date: 2024-11-18 DOI: 10.1007/s00292-024-01393-8

Andreas F-P Sonnen, Anna Vera D Verschuur, Lodewijk A A Brosens

{"title":"Diagnostic and prognostic biomarkers for pancreatic neuroendocrine neoplasms.","authors":"Andreas F-P Sonnen, Anna Vera D Verschuur, Lodewijk A A Brosens","doi":"10.1007/s00292-024-01393-8","DOIUrl":"10.1007/s00292-024-01393-8","url":null,"abstract":"This review examines the diagnostic and prognostic biomarkers for pancreatic neuroendocrine neoplasms (PanNENs), a heterogeneous group of tumors with expression of neuroendocrine markers. PanNENs include both well-differentiated pancreatic neuroendocrine tumors (PanNETs) and poorly differentiated pancreatic neuroendocrine carcinomas (PanNECs). The diagnosis is confirmed through markers such as chromogranin A, synaptophysin, and INSM1, which establish neuroendocrine differentiation. The World Health Organization classification categorizes PanNENs based on tumor differentiation and proliferative activity (Ki-67 and/or mitotic index) into well-differentiated PanNETs (grade 1 to grade 3) and poorly differentiated PanNECs. In most cases, the morphology and proliferation index are sufficient to distinguish PanNETs from PanNECs. However, distinguishing grade 3 PanNETs from PanNECs can be challenging on the basis of morphology and proliferative activity alone. Additional key diagnostic markers for distinguishing grade 3 PanNET from PanNEC include SSTR2A expression and molecular immunohistochemical markers such as p53, Rb1, menin, ATRX, and DAXX. PanNECs are by definition high-grade tumors with highly aggressive clinical behavior, while PanNETs have a variable prognosis that is difficult to predict using current biomarkers such as tumor grade and size. Several studies have shown that ATRX or DAXX loss is strongly associated with a higher risk of PanNET metastasis and recurrence. They are therefore key prognostic markers in PanNETs. In addition, chromosomal copy number variations can further help assess PanNET aggressiveness and prognosis. Molecular profiling is increasingly important for improving the diagnosis, treatment, and prognosis of PanNENs.","PeriodicalId":74402,"journal":{"name":"Pathologie (Heidelberg, Germany)","volume":" ","pages":"74-82"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142649827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Report of the working group on the history and ethics of pathology : 2024 Annual Meeting of the German Society of Pathology in Munich on 24 May 2024]. [病理学历史与伦理工作组报告：2024 年 5 月 24 日在慕尼黑举行的德国病理学会 2024 年年会]。

Pathologie (Heidelberg, Germany) Pub Date : 2024-11-01 Epub Date: 2024-08-29 DOI: 10.1007/s00292-024-01351-4

Till Braunschweig, Katrin Schierle

引用次数: 0

[Muscle-invasive and metastatic urothelial carcinoma of the urinary bladder : Current state of histopathologic, molecular, and immunologic prognostic and predictive factors]. [膀胱肌肉浸润性和转移性尿路上皮癌：组织病理学、分子和免疫学预后和预测因素的现状]。

Pathologie (Heidelberg, Germany) Pub Date : 2024-11-01 Epub Date: 2024-08-07 DOI: 10.1007/s00292-024-01347-0

Simone Bertz, Veronika Bahlinger, Fabienne Lange, Arndt Hartmann, Markus Eckstein

{"title":"[Muscle-invasive and metastatic urothelial carcinoma of the urinary bladder : Current state of histopathologic, molecular, and immunologic prognostic and predictive factors].","authors":"Simone Bertz, Veronika Bahlinger, Fabienne Lange, Arndt Hartmann, Markus Eckstein","doi":"10.1007/s00292-024-01347-0","DOIUrl":"10.1007/s00292-024-01347-0","url":null,"abstract":"Background: Muscle-invasive and metastatic urothelial carcinoma (UC) represents a heterogeneous disease entity with numerous morphological, molecular, and immunological phenotypes.Aims: This article aims to provide an overview of current histopathological, molecular, and immunological prognostic and predictive factors in muscle-invasive and metastatic UC.Results and discussion: Muscle-invasive and metastatic UC exhibits a wide range of divergent differentiations and histological subtypes. The correct diagnosis of these morphological variants is essential, as they may determine the clinical course and may also present specific and potentially therapeutically targetable molecular alterations (e.g., HER2 alterations in micropapillary UC). The morphological subtypes largely correlate with the six molecular consensus subtypes. Furthermore, morphological and molecular subtypes are associated with immunological properties that are relevant for modern immunotherapies, such as the PD-L1 status. Numerous immunotherapy studies in the setting of curatively treatable muscle-invasive UC will be reported in 2024 and 2025, likely leading to an increasing number of PD-L1 testing indications.","PeriodicalId":74402,"journal":{"name":"Pathologie (Heidelberg, Germany)","volume":" ","pages":"363-370"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141899120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diagnostic issues in neuroendocrine neoplasms of the lung. 肺部神经内分泌肿瘤的诊断问题。

Pathologie (Heidelberg, Germany) Pub Date : 2024-11-01 Epub Date: 2024-10-02 DOI: 10.1007/s00292-024-01360-3

Atsuko Kasajima, Günter Klöppel

引用次数: 0

[Neuroendocrine carcinomas of the gastrointestinal tract : Morphology, molecular pathology, cellular origin]. [胃肠道神经内分泌癌：形态学、分子病理学、细胞起源]。

Pathologie (Heidelberg, Germany) Pub Date : 2024-11-01 Epub Date: 2024-11-13 DOI: 10.1007/s00292-024-01386-7

Moritz Jesinghaus

{"title":"[Neuroendocrine carcinomas of the gastrointestinal tract : Morphology, molecular pathology, cellular origin].","authors":"Moritz Jesinghaus","doi":"10.1007/s00292-024-01386-7","DOIUrl":"10.1007/s00292-024-01386-7","url":null,"abstract":"Neuroendocrine carcinomas (NEC) are poorly differentiated neuroendocrine neoplasms that can occur ubiquitously in the mucosa-bearing organs of the gastrointestinal tract. Based on their morphology, they are classified into large cell (LCNEC) and small cell NEC (SCNEC). The most common form of mixed differentiation is the combination with an adenocarcinoma, referred to as mixed adenoneuroendocrine carcinoma (MANEC). NEC/MANEC exhibit a significantly poorer prognosis than the adenocarcinomas of their respective primary sites, which is inextricably linked to their typical histomorphology. Adenocarcinomas with aberrant expression of neuroendocrine markers do not show a worse clinical course. Molecularly, NEC/MANEC have a profile comparable to the adenocarcinomas of their site of origin and a profile divergent from neuroendocrine tumors. Analyses of gastric NEC/MANEC have shown frequent MYC amplifications, which are reflected in MYC signatures in various transcriptome analyses.The cellular origin of NEC remains a subject of controversial discussion. New insights are provided by a MYC-driven, genetically modified mouse model that led to the development of large gastric tumors. These tumors were histologically identified as LCNEC and were accompanied by both neuroendocrine and non-neuroendocrine precursor lesions. Using immunofluorescence, a derivation from resident neuroendocrine cells in the gastric corpus was demonstrated, suggesting that at least a portion of LCNEC may originate directly from neuroendocrine cells.","PeriodicalId":74402,"journal":{"name":"Pathologie (Heidelberg, Germany)","volume":" ","pages":"8-13"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142634244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Molecular testing in mesenchymal neoplasms: What, when, and how to test? : A review with a special focus on the value of next-generation immunochemistry as a substitute for molecular testing]. [间叶肿瘤的分子检测：检测什么、何时检测、如何检测：综述，特别关注下一代免疫化学作为分子检测替代品的价值]。

Pathologie (Heidelberg, Germany) Pub Date : 2024-11-01 Epub Date: 2024-11-25 DOI: 10.1007/s00292-024-01399-2

Abbas Agaimy

{"title":"[Molecular testing in mesenchymal neoplasms: What, when, and how to test? : A review with a special focus on the value of next-generation immunochemistry as a substitute for molecular testing].","authors":"Abbas Agaimy","doi":"10.1007/s00292-024-01399-2","DOIUrl":"10.1007/s00292-024-01399-2","url":null,"abstract":"With the widespread use of diverse modern molecular testing tools, the last two decades have seen significant advances in the classification of soft tissue neoplasms. Specifically, numerous molecularly defined new entities have been introduced and many established older entities have received more insightful molecular studies that have developed their classification further. The discrepant therapeutic and prognostic implications of this evolving complexity of the nosology of neoplastic diseases make the precise subtyping of soft tissue neoplasms unavoidable. However, these rapid developments of the modern diagnostic molecular pathology did not only offer efficient solutions to many complex classification issues, but they were accompanied by similarly complex and diverse emerging problems. Most importantly, these advances have not only challenged the historical dogma of some phenotypes that were once considered specific, but they also have questioned the value of diagnostic immunohistochemistry compared to emerging modern diagnostic molecular tools. Moreover, the central question of when to test, what to test, and how to test became more confusing. This review addresses the major molecular categories in soft tissue neoplasms, their characteristics, and the criteria to be used for selecting the most appropriate molecular diagnostic tool to be used in individual cases with a special focus on the value of next generation immunohistochemistry as a substitute for molecular testing.","PeriodicalId":74402,"journal":{"name":"Pathologie (Heidelberg, Germany)","volume":" ","pages":"37-46"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142712017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Report of the Gynaecological and Breast Pathology Working Group of the German Society of Pathology : 2024 DGP Annual Conference]. [德国病理学学会妇科和乳腺病理学工作组报告：2024 年 DGP 年会]。

Pathologie (Heidelberg, Germany) Pub Date : 2024-11-01 DOI: 10.1007/s00292-024-01372-z

Eike Burandt, Ramona Erber

引用次数: 0